EIF2AK3 and colorectal carcinoma: In contrast to studies suggesting that PERK activation exerts anti-tumor effects, treatment of CRC cells with FAM172A reduced PERK expression and eIf2α phosphorylation, leading to growth inhibition and tumor suppression [48].